Bioinformatics‐Driven Discovery of A β ‐Targeted Therapeutics and Diagnostic Biomarkers for Alzheimer′s Disease
BioMed Research International · 2026
DOI: 10.1155/bmri/8975137 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioMed Research International, 2026. Verfasst von Xin Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China, hrbmush.edu.cn. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Biomarkers, Computational Biology. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heilongjiang Provincial Natural Science Foundation.
Themen: Demenz
Abstract (Originalsprache)
The deposition of amyloid‐ β (A β ) plaque is widely recognized as one of the core pathological events of Alzheimer′s disease (AD). This study focused on uncovering potential diagnostic biomarkers and small‐molecule candidates potentially modulating A β ‐associated pathways in AD. Weighted gene coexpression network analysis (WGCNA) and machine learning identified the hub gene. Single‐nucleus RNA sequencing (snRNA‐seq) identified high‐expression cell clusters. We identified potential A β ‐binding small‐molecule candidates and calculated their binding affinities using molecular docking techniques. Based on molecular docking, we further evaluated the binding stability and conformational dynamics of the protein–ligand complex through molecular dynamics (MD) simulations. NFKBIA was identified as a hub diagnostic gene. Three small molecules, resveratrol, curcumin, and apigenin, demonstrated strong binding affinities for NFKBIA. These findings clarify the priority candidate gene and feasible strategic directions, which are expected to be translated into practical pathways for precision diagnosis and treatment of AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China, hrbmush.edu.cn.
ORCID-Profile: Xuemei Zhang
Förderung
- Heilongjiang Provincial Natural Science Foundation
Zitieren
APA
Li, X., Liu, X., Song, X., Zhou, Y., Yang, D., Wang, Y., Mao, S., Rang, X., Hong, X., Wang, X., Yue, H., Wang, D., & Zhang, X. (2026). Bioinformatics‐Driven Discovery of A β ‐Targeted Therapeutics and Diagnostic Biomarkers for Alzheimer′s Disease. BioMed Research International. https://doi.org/10.1155/bmri/8975137
Vancouver
Li X, Liu X, Song X, Zhou Y, Yang D, Wang Y, et al. Bioinformatics‐Driven Discovery of A β ‐Targeted Therapeutics and Diagnostic Biomarkers for Alzheimer′s Disease. BioMed Research International. 2026. doi:10.1155/bmri/8975137
BibTeX
@article{Li2026,
author = {Li, Xin and Liu, Xuerong and Song, Xinran and Zhou, Yinglian and Yang, Dan and Wang, Yifei and Mao, Senlin and Rang, Xinming and Hong, Xiangxiang and Wang, Xu and Yue, Hui and Wang, Duo and Zhang, Xuemei},
title = {Bioinformatics‐Driven Discovery of A β ‐Targeted Therapeutics and Diagnostic Biomarkers for Alzheimer′s Disease},
journal = {BioMed Research International},
year = {2026},
doi = {10.1155/bmri/8975137}
}
EUVIMED